Liraglutide (Victoza) was approved in 2010, followed by Saxenda (for weight loss) in 2014.33 Semaglutide (Ozempic) was approved in 2017, Wegovy (for weight loss) in 2021, and Rybelsus (oral) shortly thereafter
Updated 2023
Andreas Birkenfeld and Rebecca Erschens shared last authorship
Individuals receiving compounded formulations that include B6 may experience: Improved tolerability during dose escalation Reduced dropout rates Increased likelihood of staying with long-term therapy These potential benefits are still being explored in broader clinical settings, but they continue to gain attention through real-world provider feedback
Key Benefits and Clinical Applications Stubborn Fat Reduction AOD-9604 cream is particularly effective for areas resistant to diet and exercise, such as the lower abdomen, hips, thighs, and upper arms, helping to smooth contours and reduce localized fat deposits
doi: 10.1073/pnas.91.8.3242 12 CampbellSAGolecDPHubertMJohnsonJSalamonNBarrAet al